Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus shedding light or creating confusion?

Archives of Pediatrics and Adolescent Medicine

Volumn 156, Issue 12, 2002, Pages 1180-1181

  Klassen, Terry P ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

BRONCHIOLITIS; BUDGET; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; INFANT; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

EID: 0036951790     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.156.12.1180     Document Type: Editorial

References (11)

1. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. N Engl J Med. 2001;345:825-827.
2. Grooothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-1530.
3. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
4. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
5. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
6. Hill SR, Mitchell AS, Henry DA. Problems with interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283:2116-2121.
7. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intem Med. 1995;123:59-60.
8. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101-106.
9. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156:1034-1041.
10. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-1457.
11. Lewis S, Baird P, Evans RG, et al. Dancing with the porcupine: rules for governing the university-industry relationship. Can MedAssoc J 2001;165:783-785.